Trimedyne, Inc. (TMED) Cash Flow Statement

Net loss	-469K
Stock-based compensation	7K
Depreciation and amortization	96K
Gain on change in fair value of derivative liabilities
Loss on disposal of assets
Loss on extinguishment of debt and derivative liabilities
Trade accounts receivable	47K
Inventories	233K
Other assets	74K
Accounts payable	24K
Accrued expenses	-44K
Income tax payable
Deferred revenue	14K
Accrued warranty	-16K
Deferred rent
Accrued interest related party note
Net cash (used in) operating activities
Purchase of property and equipment	0
Net cash (used in) investing activities
Proceeds from note payable to related party
Payments on note payable to related party
Payments on senior secured note to related party
Payments on notes payable and capital leases	-90K
Net cash (used in) financing activities
Net (decrease) in cash and cash equivalents	-126K
Cash and cash equivalents at beginning of period	365K
Cash and cash equivalents at end of period	239K

Entities mentioned with TMED

View All Entities